Milestone Pharmaceuticals Inc.

MIST

Healthcare|Biotechnology|CA

$0.76

+0.07 (+10.15%)

DCF Value

$0.15

Tangible Book / Share

$0.13

Cash / Share

$1.23

About

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

Stock Price

-55.7%(1Y)

+7.1%

-37.5%

-60.3%

YTD

-62.2%

-58.8%

-74.1%

-86.3%

Pipeline Summary

14 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Terminated: 4Completed: 6Recruiting: 2Unknown: 2

Active Trials (2)

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

NCT06716021Atrial Fibrillation

Phase 3Recruiting

Enrollment: 750 participants

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

NCT05763953Paroxysmal Supraventricular Tachycardia

Phase 2Recruiting

Enrollment: 60 participants

Key Facts

Market Cap$95.0M

Employees38 (+15% YoY)

CEOJoseph G. Oliveto

IPO DateMay 9, 2019

Beta1.07

52-Week Range$0.6307 – $3.06

Avg Volume1,275,984

ExchangeNASDAQ

Websitemilestonepharma.com

Ownership

Float98.1%

Shares Outstanding124.5M